Pratia S.A.

The oncology team at Pratia S.A. focuses on Diffuse Large B-Cell Lymphoma, aiming to improve overall survival and progression‑free survival by testing new antibody‑based combinations with standard chemo‑immunotherapy.

• Evaluation of novel immunotherapy agents
• Comparison of combination regimens versus standard care
• Assessment of safety and tolerability in newly diagnosed patients
• Biomarker-driven patient stratification
• Impact on long‑term disease control

With 16 investigators overseeing five active trials, the site seeks to bring innovative treatments to patients across Europe.

In the realm of relapsed or refractory DLBCL, researchers evaluate multi‑agent strategies such as brentuximab vedotin combined with lenalidomide and rituximab to restore treatment response.

• Synergistic effects of antibody‑drug conjugates and immunomodulators
• Response rate optimization in resistant disease
• Patient‑reported outcomes and quality of life
• Exploratory biomarker analysis for predictive insight
• Comparative effectiveness against standard salvage therapy

These efforts reflect the department’s commitment to advancing care for patients who have exhausted first‑line options.

Beyond lymphomas, the center conducts studies on solid tumours with specific molecular alterations, exemplified by trials of bemarituzumab in FGFR2b‑positive cancers to assess antitumor activity.

• Targeted therapy based on molecular profiling
• Preliminary efficacy evaluation in diverse solid tumor types
• Safety monitoring in early‑phase investigations
• Integration of respiratory and circulatory physiological endpoints
• Translational research linking biomarkers to clinical outcomes

The program aligns with the site’s broader focus on neoplasms and related physiological processes, supporting innovative treatment options for patients in Poland and beyond.